Core Viewpoint - The company Tonghua Golden Horse has provided an update on the approval status of its new drug, indicating that it has completed all professional review work and is now in the comprehensive review stage, nearing the approval phase [2]. Summary by Categories - **Drug Approval Progress** - The new drug, Amber Dihydroaminoacridine Tablets, has completed all necessary professional review work and is currently in the comprehensive review stage, approaching the approval phase [2]. - The company advises stakeholders to refer to the public information from the drug review center for the latest updates on the drug's review progress [2]. - The company will disclose any information that meets the disclosure standards as per relevant regulations if significant events occur [2].

Core Viewpoint - The recent surge in stocks related to the "horse" concept reflects a speculative trend driven by emotions, with significant risks involved. Long-term stock prices are expected to revert to their intrinsic value, and investors may miss out on genuinely promising assets by chasing such themes [3][9][10]. Group 1: Stock Performance - Since July, 29 stocks with "horse" in their names have shown a notable increase, with an average rise of 59.85% year-to-date, significantly outperforming the A-share market's average increase of 33.51% [4][5]. - Seven stocks have more than doubled in value this year, with Jinma Amusement leading at a 267% increase [5][6]. - In July alone, Jinma Amusement saw a rise of over 90%, while several other "horse" stocks also experienced substantial gains [5][6]. Group 2: Market Dynamics - The market capitalization of "horse" related stocks ranges from 3.5 billion to 37.6 billion yuan, with 13 companies exceeding 10 billion yuan in market value [6]. - Despite the impressive stock performance, many of these companies have reported declining revenues or losses, indicating a disparity in the underlying business fundamentals [6][7]. Group 3: Speculative Behavior - The phenomenon of "zodiac stock" speculation is characterized by irrational market behavior and information asymmetry, leading to a bubble-like environment where prices deviate from fundamental values [9][10]. - The rise of social media and financial self-media has amplified the emotional contagion effect, making simplistic narratives like "buying horse stocks in the year of the horse" more prevalent [10][11].

Core Viewpoint - Tonghua Jinma's stock price has shown a significant increase of 56.56% year-to-date, but has recently experienced a slight decline in the last few trading days [1][2]. Financial Performance - For the first half of 2025, Tonghua Jinma achieved a revenue of 650 million yuan, reflecting a year-on-year growth of 0.12%. The net profit attributable to shareholders was 16.80 million yuan, marking a substantial increase of 34.77% [2]. - The company has cumulatively distributed 210 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Market Activity - As of October 16, the stock price was 24.58 yuan per share, with a market capitalization of 23.756 billion yuan. The trading volume was 184 million yuan, with a turnover rate of 0.77% [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 11, where it saw a net purchase of 142 million yuan [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,500, a rise of 6.54%. The average number of tradable shares per shareholder decreased by 6.13% to 24,457 shares [2]. - Notable shareholders include Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings reported [3].

Group 1 - The core viewpoint of the news is that Tonghua Jinma has shown significant stock performance and financial growth, with a notable increase in share price and market capitalization [1][2]. - As of September 30, Tonghua Jinma's stock price increased by 64.46% year-to-date, with a market capitalization of 24.955 billion yuan [1]. - The company has experienced a net inflow of main funds amounting to 4.2117 million yuan, with significant buying activity from large orders [1]. Group 2 - Tonghua Jinma's main business revenue composition includes 59.27% from biochemical drugs, 40.56% from traditional Chinese medicine, and minimal contributions from raw materials and others [1]. - For the first half of 2025, Tonghua Jinma reported an operating income of 650 million yuan, reflecting a year-on-year growth of 0.12%, and a net profit attributable to shareholders of 16.804 million yuan, up 34.77% [2]. - The company has not distributed dividends in the last three years, with a total payout of 210 million yuan since its A-share listing [3].

证券代码：000766 证券简称：通化金马 公告编号：2025-35 通化金马药业集团股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会无否决提案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： 现场会议召开时间为：2025年9月15日下午14:30 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年9月15日9:15—9:25，9:30—11:30和13:00—15:00；通过互联网投票系统 进行网络投票的具体时间为2025年9月15日上午9:15至下午15:00期间的任意时 间。 2、召开地点：吉林省通化市二道江区金马路999号，公司七楼会议室。 出席会议的股东及股东代表共317人，代表股份207,546,714股，占公司股份 总数的21.4742%。 其中：出席现场会议的股东及股东授权委托代表共9人，代表股份 200,010,900股，占公司股份总数的20.6945%。 3、召开方式：采用现场表决与网络投 ...

吉林秉责律师事务所 关于通化金马药业集团股份有限公司 2025 年第三次临时股东会的法律意见书 致：通化金马药业集团股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国 公司法》（以下简称"《公司法》"）、《上市公司股东会规则》（以下简称"《股东会 规则》"）和《通化金马药业集团股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，吉林秉责律师事务所（以下简称"本所"）接受了通化金马药业集 团股份有限公司（以下简称"公司"）的委托，担任公司 2025 年第三次临时股东 会（以下简称"本次股东会"）特聘专项法律顾问并出具法律意见书。 本次股东会由公司董事会召集，会议召开方式为现场投票与网络投票相结合 的方式。 现场会议的召开时间：2025 年 9 月 15 日下午 14 点 30 分，会议地点为吉林 省通化市通化金马药业集团股份有限公司七楼会议室。 网络投票时间为：通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 9 月 15 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过互联网投票 系统进行网络投票的具体时间为 2025 ...

Group 1 - The core viewpoint of the news is the performance and financial metrics of Tonghua Jinma Pharmaceutical Group Co., Ltd, highlighting its stock price increase and market capitalization [1] - As of September 11, Tonghua Jinma's stock rose by 5.03%, reaching a price of 26.29 yuan per share, with a trading volume of 1.584 billion yuan and a turnover rate of 6.61%, resulting in a total market value of 25.409 billion yuan [1] - The company, established on February 26, 1993, and listed on April 30, 1997, focuses on the research, production, and sales of pharmaceuticals, with its main revenue sources being biopharmaceuticals (59.27%), traditional Chinese medicine (40.56%), raw materials (0.10%), and others (0.07%) [1] Group 2 - From the perspective of fund holdings, Guolian An Fund has a significant position in Tonghua Jinma, with its Guolian An CSI Pharmaceutical 100A fund holding 96,800 shares, accounting for 1.04% of the fund's net value [2] - The fund reduced its holdings by 47,600 shares in the second quarter, and the estimated floating profit from this investment is approximately 122,000 yuan [2] - The Guolian An CSI Pharmaceutical 100A fund, established on August 21, 2013, has a current scale of 178 million yuan, with a year-to-date return of 20.34% and a one-year return of 38.85% [2]

Core Viewpoint - Tonghua Golden Horse experienced a significant increase of 7.55% in stock price, with a trading volume of 1.863 billion yuan and a fluctuation of 16.29% on the day [2]. Trading Activity - The stock had a turnover rate of 7.68%, with institutional investors net selling 8.3439 million yuan and the Shenzhen Stock Connect net selling 18.0141 million yuan [2]. - The top five trading departments accounted for a total transaction of 9.47 billion yuan, with a net buying amount of 1.42 billion yuan [2]. - Specific trading details show that one institutional seat was involved, with a net sell of 834.39 million yuan, while the Shenzhen Stock Connect was the fourth largest buyer and second largest seller [2][3]. Fund Flow - The stock saw a net inflow of 82.5477 million yuan from major funds, with large orders contributing 74.5637 million yuan to this inflow [2]. - Over the past five days, the net inflow of major funds totaled 89.0080 million yuan [2]. Margin Trading Data - As of September 10, the margin trading balance for the stock was 1.655 billion yuan, with a financing balance of 1.648 billion yuan and a securities lending balance of 6.9283 million yuan [3]. - In the last five days, the financing balance increased by 19.5143 million yuan, representing a growth of 1.20%, while the securities lending balance rose by 871,700 yuan, marking a 14.39% increase [3].

Core Viewpoint - Tonghua Jinma's stock price has shown a significant increase of 54.01% year-to-date, despite a recent decline in the last five trading days [1][2]. Company Overview - Tonghua Jinma Pharmaceutical Group Co., Ltd. is located in Tonghua City, Jilin Province, and was established on February 26, 1993. It was listed on April 30, 1997. The company focuses on the research, production, and sales of pharmaceuticals, with 100% of its revenue derived from the pharmaceutical industry [1]. Financial Performance - For the first half of 2025, Tonghua Jinma achieved an operating income of 650 million yuan, representing a year-on-year growth of 0.12%. The net profit attributable to shareholders was 16.80 million yuan, showing a significant increase of 34.77% compared to the previous year [2]. Stock Performance - As of September 1, the stock price was 24.18 yuan per share, with a market capitalization of 23.37 billion yuan. The trading volume was 230 million yuan, with a turnover rate of 0.99% [1]. - The stock has experienced a net outflow of 6.69 million yuan from main funds, with large orders accounting for 30.51% of total buying and 29.38% of total selling [1]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 39,500, a rise of 6.54%. The average number of circulating shares per person decreased by 6.13% to 24,457 shares [2]. - The top ten circulating shareholders include notable entities such as Innovation Drug and Southern CSI 1000 ETF, with changes in their holdings noted [3]. Dividend Information - Since its A-share listing, Tonghua Jinma has distributed a total of 210 million yuan in dividends, with no dividends paid in the last three years [3].

Group 1 - The company announced it will provide a guarantee for a loan application by its wholly-owned subsidiary, Harbin Shengtai Biopharmaceutical Co., Ltd., to Yingkou Bank, with a guarantee amount not exceeding RMB 157,000 million for principal and related interest and fees [1] - The guarantee period is set for three years [1] - After this guarantee, the total external guarantee balance for the company and its subsidiaries will amount to RMB 327,500 million, which represents 145.21% of the company's audited net assets for the year 2024 [1]